Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > generic: None & fda max : 10 mg/d or 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
Dayvigo (1) · Emgality (1)
classes:
Anti-CGRP ligand monoclonal antibody (1) · Dual orexin receptor antagonist (DORA) (1)
mechanism:
Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)
uses:
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1)
starting dose:
5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
120 mg/mL prefilled syringe or autoinjector (1) · 5 mg, 10 mg tablets (1)
fda max: (Click arrow to add another value)
routes:
Oral (1) · Subcutaneous (1)
onset:
Over weeks (1) · ~30 min (1)
duration:
Monthly dosing (1) · ~7-8 hours (1)
halflife:
~17-19 hours (longer than daridorexant) (1) · ~27 days (1)
bioavailability:
Not formally established (high SC) (1) · ~44% (1)
pregnancy:
Limited data; avoid (2)
legal:
Rx (1) · Rx, Schedule IV (US) (1)

Showing below up to 2 results in range #1 to #2.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"